Last reviewed · How we verify
GNR-086
GNR-086 is a small molecule that targets the SGLT2 receptor.
GNR-086 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GNR-086 |
|---|---|
| Also known as | canakinumab, canakinumab biosimilar |
| Sponsor | AO GENERIUM |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GNR-086 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, which have been shown to improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease (PHASE3)
- A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GNR-086 CI brief — competitive landscape report
- GNR-086 updates RSS · CI watch RSS
- AO GENERIUM portfolio CI